What is the 13F Pro Quality Score for KYMR?

13F Pro ranks Kymera Therapeutics, Inc. (KYMR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KYMR's current score at https://13fpro.ai/research/KYMR (free sign-up required for the full ranking).

Which hedge funds own the most KYMR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KYMR include FMR, BAKER BROS. ADVISORS, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KYMR as soon as new 13F filings post.

Where does 13F Pro source KYMR data?

All Kymera Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Kymera Therapeutics, Inc. files with the SEC under CIK 1815442. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KYMR in?

Kymera Therapeutics, Inc. (KYMR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KYMR research updated on 13F Pro?

KYMR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kymera Therapeutics, Inc.(KYMR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1815442 KYMR stock profile & AI dashboard →

13F Pro Quality Score

29.2/100

Rank #2,418 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

87.9/100

Profitability

3.9/100

Balance Sheet

13.0/100

Earnings Quality

30.0/100

Free Cash Flow

3.9/100

Institutional Flow

92.3/100

Revenue Scale

13.9/100

Dilution Risk

2.2/100

KYMR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kymera Therapeutics, Inc. (KYMR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYMR at 29.2/100 on a 32-signal composite quality model, placing it at rank #2,418 of 2,879 stocks — the bottom half of the AI-ranked universe. KYMR scores in the top quartile across institutional flow (92.3), revenue growth (87.9). Areas of concern include profitability (3.9) and free cash flow (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Kymera Therapeutics, Inc. reports quarterly revenue of $34.4M, net income of $-69.2M, free cash flow of $-89.3M. Top institutional holders of KYMR by reported 13-F value include FMR, BAKER BROS. ADVISORS, Avoro Capital Advisors, based on the most recent SEC filings. KYMR trades on the Nasdaq exchange and files with the SEC under CIK 1815442. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYMR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kymera Therapeutics, Inc. directly from SEC EDGAR. Kymera Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 48 since 2021, currently 29.2 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Kymera Therapeutics, Inc.

Quirks, history, and lore behind KYMR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on a cutting-edge class of drugs that makes unwanted proteins simply disappear.
2
The Numbers
A small-cap biotech with no approved products yet, burning through cash on R&D — a totally normal Tuesday in drug development. Pipeline, not profit, is the whole pitch.
3
The History
Founded around 2016, the company emerged from the Boston biotech ecosystem riding a then-nascent scientific wave called targeted protein degradation — essentially teaching cells to take out their own trash.
4
The Secret
Its platform exploits the cell's own ubiquitin-proteasome system — a natural garbage-disposal pathway — to tag and destroy disease-causing proteins that traditional drugs can't touch.
5
The Lore
The company's name is a nod to chimera, the mythological beast stitched together from different creatures — fitting for drugs that are molecular hybrids designed to hijack cellular machinery.
6
The Giveaway
It's one of the leading pure-play protein degrader biotechs, building so-called degrader antibody conjugates and small-molecule degraders — its ticker even sounds like a creature from another world.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$34.4M

Net Income

Q1 2026

$-69.2M

Free Cash Flow

Q1 2026

$-89.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-50.1% YoY

$39.2MFY 2025

FY21 $72.8MFY22 $46.8MFY23 $78.6MFY25 $39.2M

Net Income

-111.9% YoY

$-311.4MFY 2025

FY21 $-100.2MFY22 $154.8MFY23 $-147.0MFY25 $-311.4M

Operating Income

-111.1% YoY

$-349.4MFY 2025

FY21 $-100.5MFY22 $-161.3MFY23 $-165.5MFY25 $-349.4M

EPS (Diluted)

-46.4% YoY

$-3.69FY 2025

FY21 $-2.09FY22 $-2.87FY23 $-2.52FY25 $-3.69

Total Assets

+202.7% YoY

$1.74BFY 2025

FY21 $605.9MFY22 $603.1MFY23 $575.8MFY25 $1.74B

Op. Cash Flow

-126.5% YoY

$-232.9MFY 2025

FY21 $-128.9MFY22 $-153.1MFY23 $-102.8MFY25 $-232.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$39.2M -50.1%	$78.6M +67.8%	$46.8M -35.7%	$72.8M +2382.3%	$2.9M
Net Income	$-311.4M -111.9%	$-147.0M -194.9%	$154.8M +254.5%	$-100.2M -143.0%	$-41.2M
Operating Income	$-349.4M -111.1%	$-165.5M -2.7%	$-161.3M -60.4%	$-100.5M -138.2%	$-42.2M
EPS (Diluted)	$-3.69 -46.4%	$-2.52 +12.2%	$-2.87 -37.3%	$-2.09	—
Total Assets	$1.74B +202.7%	$575.8M -4.5%	$603.1M -0.5%	$605.9M +419.2%	$116.7M
Operating Cash Flow	$-232.9M -126.5%	$-102.8M +32.8%	$-153.1M -18.7%	$-128.9M -820.2%	$17.9M

Get alerted when KYMR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kymera Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KYMR

FMR LLC
$974.5M11,699,950 sh
BAKER BROS. ADVISORS LP
$721.1M8,657,242 sh
Avoro Capital Advisors LLC
$622.6M7,474,747 sh
BVF INC/IL
$458.3M5,502,710 sh
BlackRock, Inc.
$421.5M5,060,876 sh
Atlas Venture Life Science Advisors, LLC
$381.3M4,578,008 sh
WELLINGTON MANAGEMENT GROUP LLP
$324.0M3,889,687 sh
Siren, L.L.C.
$265.4M3,186,830 sh
VANGUARD CAPITAL MANAGEMENT LLC
$239.9M2,880,324 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$239.4M2,874,056 sh

Fund	Value	Shares
FMR LLC	$974.5M	11,699,950
BAKER BROS. ADVISORS LP	$721.1M	8,657,242
Avoro Capital Advisors LLC	$622.6M	7,474,747
BVF INC/IL	$458.3M	5,502,710
BlackRock, Inc.	$421.5M	5,060,876
Atlas Venture Life Science Advisors, LLC	$381.3M	4,578,008
WELLINGTON MANAGEMENT GROUP LLP	$324.0M	3,889,687
Siren, L.L.C.	$265.4M	3,186,830
VANGUARD CAPITAL MANAGEMENT LLC	$239.9M	2,880,324
VANGUARD PORTFOLIO MANAGEMENT LLC	$239.4M	2,874,056

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KYMR on your watchlist

Track score changes the day Kymera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KYMR a good stock to buy?

13F Pro's AI-powered analysis of Kymera Therapeutics, Inc. (KYMR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYMR are available on the KYMR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KYMR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYMR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kymera Therapeutics, Inc.'s investment landscape.